Small Molecule Immuno-Modulators Icon

Cambridge Healthtech Institute’s 5th Annual

Small Molecule Immuno-Modulators

Towards Anti-Cancer and Autoimmunity Therapies with Oral-Bioavailability Potential

April 2-3, 2024


Activating or dampening the immune system with small molecules is the focus of Cambridge Healthtech Institute's Small Molecule Immuno-Modulators conference. The promise of a pill, which small molecule-based therapeutics can provide, eludes the recently successful biologics-based therapies for immuno-oncology or autoimmune conditions. But more importantly, larger antibody-based therapies cannot reach the many intracellular targets being revealed by scientists as key for the immune system to reach its full potential. Many of these immune-system related targets are protein complexes which have typically been difficult to drug by small molecules because the protein-protein interaction (PPI) targets have flat surfaces. However, with the advent of new approaches such as targeted protein degradation (TPD), the drug discovery field is ripe with pill-potential drug leads. Join medicinal chemistry colleagues to share strategies and stay abreast of progress in modulating the immune system for therapeutic benefit.


Coverage will likely include:


  • Molecular glues for immuno-oncology (IO) targets
  • Small molecule-based checkpoint inhibitor candidates for IO
  • Macrophage (as opposed to traditional T cell) checkpoint inhibitors
  • Innate immune system targets for autoimmunity AND cancer (STING, RIPK, NLRP3, and more)
  • Modulating the TME (tumor microenvironment) via the extracellular matrix
  • Inflammation small molecule drug targets


The deadline for priority consideration is September 15, 2023.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


We hope you can join us for the 5 concurrent day-and-a-half conferences during each half of our 19th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda.


Opportunities for Participation:


For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director and Lead Content Director for Drug Discovery Chemistry

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431